Nanjing Delova Biotech Co., Ltd.

Focusing on unmet clinical needs in pain management, Delova leverages a proprietary technology platform for long-acting drug delivery and small-molecule drug screening, among other differentiated technologies, to build a global patent protection network covering key markets.

Delova has established a robust patent protection system across major global markets and possesses the capability to conduct new drug research and regulatory submissions in both China and the U.S. The company's first product, Putanning®/QAMZOVA™, has been successfully approved and launched in both China and the U.S., making it the first new analgesic in China to receive FDA approval. The product series has the potential to reach a multi-billion RMB market.